IL297533A - Consequences of glutrimide for use in the treatment of cough - Google Patents
Consequences of glutrimide for use in the treatment of coughInfo
- Publication number
- IL297533A IL297533A IL297533A IL29753322A IL297533A IL 297533 A IL297533 A IL 297533A IL 297533 A IL297533 A IL 297533A IL 29753322 A IL29753322 A IL 29753322A IL 297533 A IL297533 A IL 297533A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- steroid
- therapy
- patients
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018141291A RU2712281C1 (ru) | 2018-11-23 | 2018-11-23 | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| PCT/RU2019/050225 WO2020106191A1 (ru) | 2018-11-23 | 2019-11-22 | Производное глутаримида для преодоления резистентности к стероидам |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297533A true IL297533A (en) | 2022-12-01 |
Family
ID=69624712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297533A IL297533A (en) | 2018-11-23 | 2019-11-22 | Consequences of glutrimide for use in the treatment of cough |
| IL283317A IL283317A (en) | 2018-11-23 | 2021-05-20 | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283317A IL283317A (en) | 2018-11-23 | 2021-05-20 | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220362230A1 (enExample) |
| EP (2) | EP4218758A3 (enExample) |
| JP (2) | JP2022508167A (enExample) |
| KR (2) | KR20220162821A (enExample) |
| CN (2) | CN114652721A (enExample) |
| AU (2) | AU2019384626A1 (enExample) |
| BR (1) | BR112021009801A2 (enExample) |
| CA (1) | CA3120882A1 (enExample) |
| CL (2) | CL2021001316A1 (enExample) |
| EA (1) | EA201992646A1 (enExample) |
| GE (4) | GEAP202215712A (enExample) |
| IL (2) | IL297533A (enExample) |
| MD (2) | MD4844C1 (enExample) |
| MX (2) | MX2021006032A (enExample) |
| MY (1) | MY209416A (enExample) |
| PH (1) | PH12021551152A1 (enExample) |
| RU (1) | RU2712281C1 (enExample) |
| WO (1) | WO2020106191A1 (enExample) |
| ZA (2) | ZA202104247B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023177329A1 (ru) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями |
| WO2023191666A1 (ru) * | 2022-03-29 | 2023-10-05 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9111874U1 (de) * | 1991-09-23 | 1991-11-21 | Haag, Richard, 7181 Satteldorf | Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten |
| EP0625045A4 (en) * | 1992-02-07 | 1995-01-18 | Albert M Kligman | METHOD FOR TREATING FLAMMABLE DERMATOS. |
| US7544772B2 (en) * | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
| US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| US20090087425A1 (en) | 2007-08-10 | 2009-04-02 | Topigen Pharmaceuticals Inc. | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| RU2404792C1 (ru) * | 2009-05-20 | 2010-11-27 | Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" | Средство для преодоления стероидной резистентности |
| US20140112913A1 (en) * | 2011-02-10 | 2014-04-24 | Genqual Corporation | Methods of prognosing and administering treatment for inflammatory disorders |
| JP2014511181A (ja) | 2011-02-24 | 2014-05-15 | ファーマキシス リミテッド | キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤 |
| CN110128406B (zh) * | 2013-04-12 | 2021-08-27 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
| RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
-
2018
- 2018-11-23 RU RU2018141291A patent/RU2712281C1/ru active
-
2019
- 2019-11-22 US US17/296,539 patent/US20220362230A1/en not_active Abandoned
- 2019-11-22 BR BR112021009801A patent/BR112021009801A2/pt not_active IP Right Cessation
- 2019-11-22 GE GEAP202215712A patent/GEAP202215712A/en unknown
- 2019-11-22 IL IL297533A patent/IL297533A/en unknown
- 2019-11-22 CN CN202210260820.9A patent/CN114652721A/zh active Pending
- 2019-11-22 EA EA201992646A patent/EA201992646A1/ru unknown
- 2019-11-22 GE GEAP201915712A patent/GEP20237467B/en unknown
- 2019-11-22 MD MDA20210050A patent/MD4844C1/ro active IP Right Grant
- 2019-11-22 GE GEAP202415619A patent/GEAP202415619A/en unknown
- 2019-11-22 CN CN201980076564.4A patent/CN113164464A/zh active Pending
- 2019-11-22 KR KR1020227040632A patent/KR20220162821A/ko not_active Ceased
- 2019-11-22 CA CA3120882A patent/CA3120882A1/en active Pending
- 2019-11-22 GE GEAP201915619A patent/GEP20247643B/en unknown
- 2019-11-22 AU AU2019384626A patent/AU2019384626A1/en not_active Abandoned
- 2019-11-22 KR KR1020217019084A patent/KR20210095652A/ko not_active Withdrawn
- 2019-11-22 WO PCT/RU2019/050225 patent/WO2020106191A1/ru not_active Ceased
- 2019-11-22 MX MX2021006032A patent/MX2021006032A/es unknown
- 2019-11-22 JP JP2021528866A patent/JP2022508167A/ja active Pending
- 2019-11-22 MY MYPI2021002768A patent/MY209416A/en unknown
- 2019-11-22 MD MDA20210032A patent/MD4851C1/ro active IP Right Grant
- 2019-11-22 EP EP22210617.1A patent/EP4218758A3/en active Pending
- 2019-11-22 EP EP19886166.8A patent/EP3884945A4/en not_active Withdrawn
-
2021
- 2021-05-19 CL CL2021001316A patent/CL2021001316A1/es unknown
- 2021-05-20 PH PH12021551152A patent/PH12021551152A1/en unknown
- 2021-05-20 IL IL283317A patent/IL283317A/en unknown
- 2021-05-21 MX MX2022013503A patent/MX2022013503A/es unknown
- 2021-06-21 ZA ZA2021/04247A patent/ZA202104247B/en unknown
-
2022
- 2022-03-21 CL CL2022000683A patent/CL2022000683A1/es unknown
- 2022-09-21 ZA ZA2022/10444A patent/ZA202210444B/en unknown
- 2022-10-21 AU AU2022256212A patent/AU2022256212B2/en active Active
- 2022-11-17 JP JP2022184210A patent/JP7518997B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hanania | Targeting airway inflammation in asthma: current and future therapies | |
| EP2969010B1 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| US6930093B2 (en) | Use of ribofuranose derivatives against inflammatory bowel diseases | |
| AU2022256212B2 (en) | Glutarimide derivative for overcoming resistance to steriods | |
| CN113614070A (zh) | 中性粒细胞弹性蛋白酶抑制剂在肝病中的用途 | |
| JP2005508346A (ja) | 免疫炎症疾患の治療のための組合せ | |
| EP3256124B1 (en) | Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis | |
| CN109432431B (zh) | 一种含有sumo抑制剂的组合物及应用 | |
| US20090247558A1 (en) | Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases | |
| WO2011131705A1 (en) | Treatment of multiple sclerosis with masitinib | |
| US11439631B2 (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
| JP2016153374A (ja) | 炎症性疾患を治療又は予防するための医薬組成物 | |
| OA20849A (en) | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling. | |
| EA046267B1 (ru) | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма | |
| OA20833A (en) | Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling. | |
| JP2021075469A (ja) | 植物由来アルカロイドを含有する医薬組成物 | |
| EA043839B1 (ru) | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма | |
| HK40074427A (en) | USE OF GLUTARIMIDE DERIVATIVES FOR OVERCOMING STEROID RESISTANCE AND TREATING DISEASES ASSOCIATED WITH ABERRANT INTERFERON γ SIGNALING | |
| HK40059361A (en) | Glutarimide derivative for overcoming resistance to steriods | |
| EP3903778A1 (en) | Immunosuppressive pharmaceutical composition and application thereof | |
| WO2023143446A1 (en) | Compositions and methods for treating cytokine storm | |
| US20240226057A1 (en) | New use of monensin | |
| JP2001512446A (ja) | メラニンによるサイトカインの調整 | |
| WO2023202439A1 (zh) | 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用 | |
| Aumais et al. | Rectal tissue, plasma, and urine concentrations of mesalamine (5-ASA) after single and multiple administrations of suppositories to ulcerative proctitis (UP) patients |